Middle East & Africa Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

The Middle East & Africa infectious disease diagnostics market was valued at US$1.19 billion in 2022 and is expected to reach US$1.57 billion by 2030; it is estimated to grow at a CAGR of 3.5% from 2022 to 2030.

Rising Incidence of Infectious Diseases Drive Middle East & Africa Infectious Disease Diagnostics Market

Fungi, viruses, parasites, bacteria, and toxic products are among the infectious agents that can cause infectious diseases. Public health is adversely affected by infectious diseases, causing morbidity, mortality, and economic burdens. Rising incidence of infectious diseases propels the requirement for accurate and timely diagnosis to form the basis for effective disease management, treatment, and prevention. Diagnosing and monitoring multiple infections and diseases, including hepatitis C, HIV, tuberculosis, human papillomavirus, and sexually transmitted infections (STIs), and infectious disease outbreaks can be performed using molecular diagnostics techniques, laboratory-based assays, and point-of-care tests. According to the Centers for Disease Control and Prevention (CDC), ~10.2 million people visited physician offices for the treatment of infectious and parasitic diseases in African countries every year. According to an article published in the National Library of Medicine (NLM) in 2021, infectious diseases are a major concern in most African countries due to high disease burden and limited healthcare resources. More than 200 pathogens can cause fever in Nigeria, one of the most common reasons for visiting a healthcare facility. According to the World Health Organization (WHO), ~58 million people across the world suffer from chronic hepatitis C infection, and ~1.5 million new infections are diagnosed every year. HIV is a major public health issue across the world. According to The Joint United Nations Program on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, ~36 million people were adults, and about 1.7 million were children aged 0-14 years. Also, ~1.5 million new HIV cases were reported globally in 2020. According to WHO, tuberculosis (TB) is the 13th leading cause of death across the world, and it is the second leading infectious disease that leads to death after COVID-19. According to the WHO, 1.5 million deaths were caused by TB in 2020. In 2020, WHO projected that 10 million people had TB across the world, Furthermore, in 2020, 30 countries with high TB burdens accounted for 86% of new TB cases. Thus, the upsurging incidence of infectious diseases bolsters the need for infectious disease diagnostic technologies, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA).

Middle East & Africa Infectious Disease Diagnostics Market Overview

The Rest of Middle East & Africa includes Israel, Iran, Iraq, Kuwait, Oman, Egypt, and Kenya. Increasing demand for infectious disease diagnostics and growing technological advancement in clinical diagnostic technologies are boosting the market growth in the Middle Eastern and Africa. Moreover, the presence of major market players in the countries in the Rest of Middle East and Africa is fueling the growth of the market. for instance, Todos Medical Ltd. is a leading company in Israel that deals with providing life-saving diagnostic solutions for the early detection of various diseases. In 2021, the company has announced its first commercial antibody test for COVID-19. Thus, the presence of players offering products and end users related, the development and innovation of diagnostic solutions in various countries of the region is further likely to be responsible for supporting the overall growth of the market.

Middle East & Africa Infectious Disease Diagnostics Market Segmentation

The Middle East & Africa infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.

Based on product, the Middle East & Africa infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.

By technology, the Middle East & Africa infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The molecular-based diagnostic techniques segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the Middle East & Africa infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.

By testing type, the Middle East & Africa infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the Middle East & Africa infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.

Based on country, the Middle East & Africa infectious disease diagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa infectious disease diagnostics market in 2022.

Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the Middle East & Africa infectious disease diagnostics market.